High serum IL-13 is associated with non- small cell lung cancer

Data suggest that interleukin 33 (IL-33) may play an important role in the development of non-small cell lung cancer (NSCLC) and the targeted therapy.

This study demonstrates that the presence of rs928413(G) allele in the IL33 promoter results in its increased activity in a human lung carcinoma cell line due to binding of the cAMP (cyclic adenosine monophosphate) response element binding protein 1 (CREB1) transcription factor. The results offer a tentative explanation for the negative effect of rs928413 on asthma development.

In a Chinese Han population, we identified ADRB2 polymorphisms (rs1042711 and rs1560642) that were associated with increased risk of lung cancer, and polymorphisms in IL33 (rs7025417) and IL2RB (rs5756523 and rs2284033) that were associated with decreased disease risk.

Study described a novel mechanism for IL-33-mediated suppression of the development of tumor metastasis, where IL-33 administration substantially enhanced the activation and specific recruitment of NK cells to the tumor site in the 4T1 breast cancer pulmonary metastatic model. Furthermore, IL33 expression was positively correlated with NK cell activation and with improved prognosis in breast cancer patients.

[Regulation of IL33 Gene expression by SP1 and Foxa1 in Breast and lung cancer Cells].

IL-33 stimulated NF-kappaB signaling and promoted the proliferation, activation and infiltration of CD8(+) T cells and NK cells, which resulted in the inhibition of pulmonary metastasis in B16 melanoma and Lewis lung carcinoma mice models.

IL33 activates CD8+T and NK cells through MyD88 pathway to suppress the lung cancer cell growth in mice.